Arbutus Biopharma
ABUS
59 hedge funds and large institutions have $67.4M invested in Arbutus Biopharma in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 10 increasing their positions, 18 reducing their positions, and 11 closing their positions.
127% more capital invested
Capital invested by funds: $29.7M → $67.4M (+$37.8M)
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
7% more funds holding
Funds holding: 55 → 59 (+4)
4.82% more ownership
Funds ownership: 34.24% → 39.07% (+4.8%)
44% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$5.99M |
| 2 |
Jennison Associates
New York
|
+$3.53M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.07M |
| 4 |
CAC
Cowen and Company
New York
|
+$1.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$464K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
-$5.57M |
| 2 |
BlackRock
New York
|
-$922K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$763K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$469K |
| 5 |
Renaissance Technologies
New York
|
-$257K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FHA
51
Flagship Harbor Advisors
Boston,
Massachusetts
| $1K | – | – | – |
|
|
NFG
52
Next Financial Group
Houston,
Texas
| $1K | – | – | – |
|
53
BNP Paribas Financial Markets
Paris,
France
| $195 | -$6.3K | -3,892 | -98% |
|
|
SFM
54
Sphera Funds Management
Tel Aviv,
Israel
| – | -$763K | -500,000 | Closed |
|
|
55
Renaissance Technologies
New York
| – | -$257K | -168,312 | Closed |
|
56
JP Morgan Chase
New York
| – | -$145K | -95,146 | Closed |
|
|
TRCT
57
Tower Research Capital (TRC)
New York
| – | -$62.6K | -38,689 | -100% |
|
58
SG Americas Securities
New York
| – | -$54K | -35,701 | Closed |
|
|
LP
59
LMR Partners
London,
United Kingdom
| – | -$44K | -29,104 | Closed |
|
60
Walleye Trading
New York
| – | -$35K | -22,658 | Closed |
|
61
Walleye Capital
New York
| – | -$34K | -22,572 | Closed |
|
62
ProShare Advisors
Bethesda,
Maryland
| – | -$23K | -15,394 | Closed |
|
|
MAM
63
Meeder Asset Management
Dublin,
Ohio
| – | -$9K | -5,716 | Closed |
|
64
Group One Trading
Chicago,
Illinois
| – | -$5.08K | -3,140 | Closed |
|
ABUS Hedge Fund Activity: Q4 2019 in Review
59 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2019, worth a combined $67.4M — up 127% from $29.7M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ABUS positions and 11 closed out — a net gain of 4 holders — while 10 added to existing stakes and 18 trimmed.
The largest buyer was Foresite Capital Management IV, opening a new position worth an estimated $5.99M. The largest seller was Primecap Management, cutting an estimated $5.57M.
- 59 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2019, up from 55 in Q3 2019.
- Funds reported $67.4M of Arbutus Biopharma stock for Q4 2019, up 127% quarter-over-quarter.
- 15 funds opened new Arbutus Biopharma positions in Q4 2019 and 11 closed out, a net change of +4 holders.
- The largest Arbutus Biopharma buyer in Q4 2019 was Foresite Capital Management IV, an estimated $5.99M added.
- The largest Arbutus Biopharma seller in Q4 2019 was Primecap Management, an estimated $5.57M sold.
Based on aggregated 13F filings for Q4 2019.